Table 1.
Demographic characteristics of the study population at the baseline.
| Active (Group A) |
Placebo (Group B) |
p | |
|---|---|---|---|
| Gender (m/w) | 23/20 | 21/21 | 0.901 |
| Age (years) | 65.12 ± 11.16 | 62.34 ± 11.32 | 0.323 |
| Height (cm) | 170.27 ± 8.64 | 165.44 ± 11.7 | 0.062 |
| Body weight (kg) | 89.85 ± 12.5 | 85.22 ± 15.27 | 0.185 |
| Body Mass Index (BMI) (kg/m2) | 30.99 ± 3.78 | 31.19 ± 4.99 | 0.859 |
| Diabetes Duration (years) | 15.01 ± 8.2 | 14.6 ± 9.7 | 0.824 |
| Metformin + other oral antidiabetic drugs (%) | 24 (55.8) | 22 (53.4) | 0.718 |
| Duration of receiving Metformin (years) | 14.5 ± 8.5 | 13.2 ± 9.4 | 0.554 |
| Smoking (%) | 14 (32.5) | 14 (35.7) | 0.724 |
| Cardiovascular disease (%) | 15 (34.9) | 13 (30.9) | 0.633 |
| Hyperlipidemia (%) | 32 (74.4) | 30 (71.4) | 0.710 |
| Hypertension (%) | 28 (65.1) | 28 (66.7) | 0.847 |
Data are given as means +/− standard deviation or n (%).